

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/603,566	06/25/2003	Valerie Wittamer	9409/2045B	7945
29933 7	2590 09/15/2006		EXAMINER	
PALMER & DODGE, LLP KATHLEEN M. WILLIAMS 111 HUNTINGTON AVENUE			LI, RUIXIANG	
			ART UNIT	PAPER NUMBER
BOSTON, MA			1646	
			DATE MAILED: 09/15/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	10/603,566	WITTAMER ET AL.		
Office Action Summary	Examiner	Art Unit		
	Ruixiang Li	1646		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed on 27 Ju	action is non-final. nce except for formal matters, pro	•		
Disposition of Claims				
4) ☐ Claim(s) 1-10,20 and 22 is/are pending in the a 4a) Of the above claim(s) 6-9 is/are withdrawn is 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-5, 10, 20, and 22 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	from consideration.			
Application Papers	•			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 11.	epted or b) objected to by the I drawing(s) be held in abeyance. See ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119		•		
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 02/07/2006.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate		

DETAILED ACTION

Status of Application, Amendments, and/or Claims

The amendment filed on 06/27/2006 has been entered in full. Claims 1-10, 20, and 22 are pending. Claims 1-5, 10, 20, and 22 are under consideration.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

Withdrawn Objections and/or Rejections

The rejection of claims 1-5 under 35 U.S.C. 101 has been withdrawn in view of the amended claims.

Information Disclosure Statement

The information disclosure statement filed on 02/07/2006 has been considered by the examiner.

Claim Rejections under 35 U.S.C. § 102 (b)

The rejection of claims 1-5 and 20 under 35 U.S.C. 102(b) as being anticipated by Nagpal et al. (*J. Invest. Dermatol.* 109: 91-95, 1997) is maintained.

Applicants argue that Napal et al. do not teach a polypeptide comprising all the limitations of the polypeptides instantly claimed. Specifically Nagpal et al. does not

teach a polypeptide that binds specifically to a chemerinR polypeptide, as required by

claim 1 and its dependent claims.

Applicants' argument has been fully considered, but is not deemed to be persuasive for

the following reasons. The instant claims are drawn to an isolated peptide comprising

SEQ ID NO: 61 and a composition comprising the polypeptide of SEQ ID NO: 61. The

cited prior art teaches a polypeptide that comprises the polypeptide of SEQ ID NO: 61.

Thus, the prior art teaches the same polypeptide, whereas any properties of the

polypeptide are inherent to its structure.

Claim Rejections under 35 U.S.C. § 102 (e)

The rejection of claims 1-5, 10, 20, and 22 under 35 U.S.C. 102(e) as being anticipated

by Lal et al. (US Patent Application Publication No. 2005/0084936 A1, publication date:

April 21, 2005; 102 (e) date: December 31, 1997) is maintained.

Applicants argue that Lal et al. do not teach a polypeptide comprising all the limitations

of the polypeptides instantly claimed. Specifically Lal et al. do not teach a polypeptide

that binds specifically to a chemerinR polypeptide, as required by claim 1 and its

dependent claims.

Applicants' argument has been fully considered, but is not deemed to be persuasive for

the following reasons. The instant claims are drawn to an isolated peptide comprising

SEQ ID NO: 61 and a composition comprising the polypeptide of SEQ ID NO: 61. The

cited prior art teaches a polypeptide that comprises the polypeptide of SEQ ID NO: 61.

Thus, the prior art teaches the same polypeptide, whereas any properties of the

polypeptide are inherent to its structure.

Conclusion

No claims are allowed.

THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the

extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within

TWO MONTHS of the mailing date of this final action and the advisory action is not

mailed until after the end of the THREE-MONTH shortened statutory period, then the

shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later

than SIX MONTHS from the date of this final action.

Page 4

Application/Control Number: 10/603,566

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the

Page 5

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Nickol, can be reached on (571) 272-0835. The fax number for the

organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, please contact the Electronic

Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruixiang Li, Ph.D.

Primary Examiner

September 5, 2006

RUIXIANG LI, PH.D. PRIMARY EXAMINER